TO 6 warrants

In August 2024, Dicot Pharma conducted a rights issue that was subscribed to 124 percent. All those who were allocated shares in the issue also received, free of charge, warrants in series TO 6. Many have since actively purchased warrants on the market. These can now be exercised during the subscription period from March 17 to March 31.

"We are extremely pleased with the strong support in the issue from our existing shareholders and new investors. The oversubscription of the rights issue highlights the significant interest in Dicot Pharma and a strong confidence in our pharmaceutical development. We have great optimism for the future and want to express our sincere gratitude to everyone who has supported us. We will make sure to handle this trust with care."

CEO Elin Trampe, in September 2024, after the outcome of the issue was announced.

For each warrant you hold, two new shares can be subscribed for at a price of 0.19 SEK per share. Thus, 1,000 warrants entitle the holder to subscribe for 2,000 shares for a total of 380 SEK. The price corresponds to 70% of the average share price from February 24 to March 10.

Major shareholders in Dicot Pharma and all members of the board and management holding warrants of series TO 6 have declared their intention to exercise them. This corresponds to a total investment of approximately SEK 11 million, or about 24 percent of the total outstanding warrants.

Upon full subscription, Dicot Pharma will receive approximately 45.7 million SEK before costs. The proceeds will be a significant contribution that enables maintaining a high pace forward and bringing us ever closer to launch. The proceeds are intended to be allocated as follows:

Co-financing of the clinical phase 2b study, scaling up the supply chain, and other preparations to make the company phase 3-ready as soon as possible (approximately 80%).
Evaluation and development to expand the product portfolio with new indications, including metabolic diseases (approximately 20%).

Summary of the Offer

Offer and Issue Volume
Each warrant in series TO 6 entitles the holder to subscribe for two new shares in Dicot Pharma. The subscription price is 0.38 SEK per warrant, corresponding to 0.19 SEK per share, which is approximately 70% of the average share price from February 24 to March 10, 2025.

Upon full utilization, 240,304,502 shares will be issued, providing Dicot Pharma with a maximum of approximately 45.7 million SEK before issue costs.

Subscription Period
The subscription period is from March 17 to March 31, 2025. Please note that banks set their own deadlines for subscription, so make sure to check what applies to your bank.

Trading of TO 6 Warrants
Warrants can be bought and sold until March 27 under the ticker "DICOT TO 6" via Avanza, Nordnet, or other banks. Note that warrants that are not exercised during the subscription period will expire worthless.

By purchasing warrants before March 27, you obtain more TO 6 to use for subscribing to shares. If you are unable or unwilling to participate in the redemption, you can sell your warrants, thereby giving others the opportunity to participate.

How to Subscribe
If you use Avanza, Nordnet, or a bank as a custodian, follow their instructions. Be aware that processing times may vary, so make sure to act in good time before March 31.

If you hold your TO 6 in a securities account or VP account, a partially pre-filled form will be mailed to you, which must be returned to Aqurat Fondkommission no later than March 31, 2025, at 3:00 PM. The form will also be available for download on this page.

Questions and Answers
Please contact us if you have any questions regarding the warrants. You can reach us at [email protected] or by phone: